Trending Now - GLP-1 Medications: Weight Loss Gains and Cognitive Concerns
WHO:
WPEC - Jennifer Kirtley, a patient who lost 180 pounds using Wegovy shots.
WPEC - Dr. Leonard J. Pianko, founder and medical director of the Aventura Cardiovascular Center.
WPEC - Dr. Armando Hernandez-Rey, a South Florida fertility specialist.
WPEC - Dr. Sonya Daryanani, internist and obesity specialist with Nova Southeastern University.
WPEC - Dr. Jacob Tangir, with The Center for Gynecologic Oncology in Miramar.
WPEC - Dr. Gil Lichtshein, a Boca Raton psychiatrist.
WPEC - Dr. Jeffrey Fromowitz, a Boca Raton dermatologist.
WPEC - Dr. Manisha Chand, an obesity medicine specialist at the Cleveland Clinic Weston.
WPEC - Dr. George Kamal, a South Florida plastic surgeon.
WPEC - Dr. William Hinojosa, an Oklahoma surgeon.
Futurism - Isaac Thorman, an epidemiology researcher at Johns Hopkins University School of Medicine.
WHAT:
WPEC - Jennifer Kirtley reported that her blood pressure and A1C levels have decreased, and she has no desire to drink alcohol after losing 180 pounds on Wegovy.
WPEC - A 2023 study of over 17,000 patients found that semaglutide reduced the risk of major cardiovascular events by about 20% in overweight or obese adults with cardiovascular disease but not diabetes.
WPEC - A 2025 study found that GLP-1 medications are associated with a 17% lower risk of developing 14 obesity-associated cancers, including endometrial, meningioma, and ovarian cancers.
WPEC - A meta-analysis of 76 randomized clinical trials indicated that the risk of gallbladder problems increases when weight-loss medications are used at higher doses and for longer durations.
WPEC - Jennifer Kirtley lost 180 pounds and is now a size 6.
WPEC - A 2023 study published in the New England Journal of Medicine found that semaglutide reduced the risk of major cardiovascular events by about 20% in overweight or obese adults with cardiovascular disease.
WPEC - The FDA approved Wegovy (semaglutide) injection to treat metabolic-associated steatohepatitis (MASH) in adults.
WPEC - Approximately 6% of U.S. adults, or about 14.9 million people, have MASH.
WPEC - A 2025 study found GLP-1 medications are associated with a 17% lower risk of developing 14 obesity-associated cancers.
Futurism - A retrospective study found that GLP-1 drug users had a 2.6% rate of cognitive impairment compared to 1.3% for non-users.
WHERE:
WPEC - Lake Worth Beach, Florida, where Jennifer Kirtley resides.
WPEC - South Florida, where various clinicians and specialists are observing the effects of GLP-1 medications.
Futurism - Data analyzed from over 100 healthcare organizations across five countries.
WHEN:
WPEC - The FDA approval for Wegovy to treat MASH occurred after clinical trials.
Futurism - The retrospective study was presented at the American Academy of Neurology annual meeting.
WHY:
WPEC - Dr. Gil Lichtshein noted that GLP-1 medications might have promising benefits in reducing substance abuse, including alcohol and opioids.
WPEC - GLP-1 medications suppress appetite and increase feelings of fullness, aiding in diabetes and obesity management.
WPEC - The study by Isaac Thorman suggests that GLP-1 users may experience cognitive impairment due to living longer, not necessarily because of the drug itself.
HOW:
WPEC - Dr. Manisha Chand stated that combining GLP-1 therapy with strength training and ensuring adequate nutrient intake can help protect bone health.
WPEC - GLP-1 medications work by slowing digestion and helping patients feel full longer, which reduces overall calorie intake.
Futurism - The study tracked nearly 65,000 type 2 diabetes patients over a ten-year span to analyze the effects of GLP-1 drugs.
(UPDATED April 26, 2026 15:10 UTC)
Jennifer Kirtley has reported significant health improvements after losing 180 pounds on Wegovy, noting decreased blood pressure and A1C levels, along with a newfound aversion to alcohol. A recent study revealed that semaglutide, a GLP-1 medication, can lower the risk of major cardiovascular events by about 20% in overweight or obese adults with cardiovascular disease, while another study found it may also reduce the risk of certain obesity-related cancers by 17%. Experts suggest that combining GLP-1 therapy with strength training and proper nutrition can help maintain bone health, and there are indications that these medications may also aid in reducing substance abuse issues.
--
(UPDATED April 26, 2026 05:48 UTC)
Jennifer Kirtley, a resident of Lake Worth Beach, Florida, has successfully lost 180 pounds using Wegovy shots and now fits into a size 6. A recent study published in the New England Journal of Medicine found that semaglutide, the active ingredient in Wegovy, can reduce the risk of major cardiovascular events by about 20% in overweight or obese adults with cardiovascular disease, while another study indicated that GLP-1 medications are linked to a 17% lower risk of developing obesity-associated cancers. Additionally, a retrospective study presented at the American Academy of Neurology annual meeting revealed that GLP-1 drug users had a 2.6% rate of cognitive impairment compared to 1.3% for non-users, suggesting that the cognitive effects may be related to longevity rather than the medication itself.